Comparative analysis of whether neratinib (neratinib) can replace pyrotinib treatment options

Neratinib (Neratinib) and pyrotinib are both irreversible pan-HER inhibitors and are widely used in the targeted treatment of HER2-positive breast cancer. However, there are differences in clinical indications, timing of use, side effects, and approved regions, so they are not completely substitutes. Although the two have similar mechanisms of action, both block cancer cell signaling pathways by inhibiting receptor tyrosine kinases such as HER2 and EGFR, but their clinical positions have different focuses.

Neratinib is mainly used for postoperative adjuvant treatment of early-stage HER2 positive breast cancer, especially for patients who are still at high risk of recurrence after trastuzumab treatment. It was shown in the ExteNET study to reduce the long-term recurrence rate and is suitable as postoperative consolidation therapy. In contrast, pyrotinib is currently mainly used for the second-line and above treatment of advanced HER2-positive breast cancer. It is especially suitable for patients after chemotherapy with capecitabine. It has outstanding efficacy and is widely used in the Chinese market and has been included in medical insurance.

In terms of substitution, pyrotinib is more accessible to Chinese patients and is relatively cheap; neratinib has not yet been officially launched in mainland China and needs to be obtained through overseas channels. The cost is higher and it is mainly used in the postoperative adjuvant stage rather than late-stage treatment. Therefore, from the perspective of clinical applicability, neratinib is not suitable to directly replace pyrotinib for the treatment of advanced breast cancer. The two should be used as complementary options at different stages in the treatment chain.

Overall, neratinib and pyrotinib play different roles in the treatment strategy of HER2positive breast cancer. If the patient is at a high-risk stage for postoperative recurrence and hopes to prolong disease-free survival, neratinib may be considered; for patients who have entered an advanced stage and need to control progression, pyrotinib is still the mainstream choice. When formulating treatment plans, doctors should comprehensively evaluate drug selection strategies based on the patient's disease stage, previous medication history, and economic conditions.

Reference materials:https://www.drugs.com/

xa0